Covid 19 roundup: Trump push­es his new fa­vorite, untest­ed drug; CRISPR out­lines crip­pling im­pact of Covid-19

8 minutes ago
Coronavirus

UP­DAT­ED: Have a new drug that promis­es to fight Covid-19? The FDA promis­es fast ac­tion but some de­vel­op­ers aren't hap­py

2 hours ago
Coronavirus
Regulatory

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

23 hours ago
Regulatory

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

Yesterday
Coronavirus

Eli Lil­ly antes up $60M gam­ble on a dis­cov­ery deal with GSK-backed biotech

Yesterday
Deals

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Yesterday
R&D

Covid-19 and weak da­ta force pipeline re­vamp at Rea­ta, but the best tri­als go for­ward — with some cre­ative adap­tions

Yesterday
Coronavirus
R&D

David Hal­lal bags an­oth­er whop­per round, look­ing to re­cruit more cell and gene ther­a­py up­starts to El­e­vate­Bio Base­Camp

Yesterday
R&D
Startups

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

2 days ago
Pharma
R&D

IL-6 to the res­cue? Sanofi, Re­gen­eron bar­rel ahead in­to an­oth­er piv­otal ef­fort test­ing Kevzara for Covid-19

2 days ago
Coronavirus
Deals

Gilead CEO Dan O'­Day of­fers a de­tailed ex­pla­na­tion on remde­sivir ac­cess — re­as­sur­ing an­a­lysts that Covid-19 da­ta are com­ing fast

2 days ago
Coronavirus
R&D

As share buy­backs come un­der scruti­ny, what's in store for the bio­phar­ma in­dus­try?

4 days ago
Coronavirus
R&D

A Sin­ga­pore VC rais­es $200M for a new round, but will Covid-19 pre­vent it from rais­ing the rest?

5 days ago
Coronavirus
Venture

Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

5 days ago
Coronavirus
R&D

Pfiz­er, My­lan deal takes a coro­n­avirus hit

5 days ago
Coronavirus
Deals

Kept on hold at the FDA, Ipsen scraps a key tri­al and re­vamps R&D path for its trou­bled $1B-plus rare dis­ease drug

6 days ago
R&D
Regulatory

Covid-19 roundup: In­ter­cept, blue­bird and a grow­ing list of biotechs feel the pain as pan­dem­ic man­gles FDA, R&D sched­ules

6 days ago
Coronavirus

Bris­tol My­ers bags a long-await­ed FDA OK for ozan­i­mod — but the pan­dem­ic will keep it off the mar­ket

6 days ago
Pharma
Regulatory

Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

6 days ago
Coronavirus
Pharma

Roche forges deal with San Diego biotech, bet­ting on new an­tibi­ot­ic class

6 days ago
Deals

Covid-19 roundup: Bris­tol My­ers sus­pends clin­i­cal tri­als, grounds field team; Vir ush­ers an­ti­body can­di­dates to hu­man test­ing

6 days ago
Coronavirus

The first big hur­dle on the Cel­gene CVR ar­rives to­day. Can Bris­tol My­ers clear a low bar in the mid­dle of a pan­dem­ic?

Last week
Regulatory

Mod­er­na CEO Stéphane Ban­cel out­lines a short path for emer­gency use of a coro­n­avirus vac­cine

Last week
Coronavirus

Join­ing No­var­tis in siR­NA space, As­traZeneca hands Si­lence $80M up­front for dis­cov­ery deal

Last week
Deals
Discovery
1234 Next page Last page